Jam

Rezolve Ai (RZLV) refuted a report by Fuzzy Panda Research, a firm shorting RZLV stock, calling it a manipulation attempt. CEO Wagner defended partnerships with Microsoft, Google, and Tether, reaffirming revenue figures validated by audits and SEC filings. The company highlighted its *brainpowa* AI platform and patents. Rezolve will address concerns at its October 1, 2025, earnings announcement.

SonicStrategy Inc. announced Dustin Zinger as CEO, replacing Mitchell Demeter who becomes Executive Chair and CEO of Sonic Labs. This aims to strengthen validator operations and network growth. The company also commenced trading on the Frankfurt Stock Exchange and initiated a €100,000 marketing campaign to target European investors. The leadership shift and expanded market presence are designed to accelerate growth in the blockchain validation market.

Chipotle is launching Red Chimichurri, a limited-time offering, in the U.S. and Canada on September 30th to attract Gen Z and differentiate itself in the fast-casual market. This vibrant sauce, featuring roasted garlic, cilantro, chili peppers, and citrus, complements dishes like Carne Asada. Chipotle Rewards members get a free sample on launch day. This move builds on previous successful limited-time items and reflects Chipotle’s focus on flavor innovation and culinary development. The company recommends pairing Red Chimichurri with select entrees.

Nordic American Tankers (NAT) will hold its Annual General Meeting (AGM) on November 21, 2025. The record date for shareholder voting eligibility is September 12, 2025. The Notice of Meeting and Proxy Statement will be filed with the SEC via Form 6-K after market close on September 29, 2025. Shareholders will receive detailed information about the meeting and voting procedures.

Murex and AWS are expanding their partnership, integrating Murex’s MX.3 platform as managed services on AWS. This offers financial institutions enhanced functionality, security, and operational excellence. The collaboration focuses on accelerating deployment and upgrades, expanding Murex’s SaaS offering (MXSaaS) and cloud-native XVA as a Service leveraging AWS’s scalability. MXSaaS has already gained four new customers since June. Murex is investing heavily in scaling MXSaaS operations. The aim is to provide agility, flexibility, and resilience, optimizing the client experience.

Genmab will acquire Merus for $97.00 per share in cash, a deal valued at approximately $8.0 billion. This acquisition adds petosemtamab, a late-stage asset with Breakthrough Therapy Designations for head and neck cancer, to Genmab’s portfolio. Petosemtamab has shown promising Phase 2 data and is currently in Phase 3 trials. Genmab anticipates the acquisition accelerating its business model transition, broadening revenue streams and being accretive to EBITDA by the end of 2029. The deal is expected to close in early 2026, pending customary approvals.

CLINUVEL (NASDAQ:CLVLY) announced advancements in novel sustained-release liquid drug formulations after 10 years of research. The company is proceeding to preclinical evaluation of drug release profiles, aiming to extend peptide drug release, especially melanocortins, using biocompatible systems for flexible dosing. This technology may benefit diverse patient groups. The preclinical program’s completion is expected in H2 2026. The new depot formulations would serve as a platform for the delivery of various peptides, with an initial focus on melanocortins.

Tommy Fleetwood received the Nicklaus-Jacklin Award after the 2025 Ryder Cup, recognizing his embodiment of the event’s spirit through integrity and sound decision-making. Fleetwood’s impressive 4-1-0 record contributed significantly to Team Europe’s victory. Beyond his performance, his composure and sportsmanship, echoing the 1969 Nicklaus-Jacklin moment, earned him the honor. Aon, the award presenter, highlighted Fleetwood’s leadership and ability to make better decisions under pressure, mirroring Aon’s values. Team Europe secured a 15-13 victory overall, winning on US soil.

Barton Gold has commenced a Definitive Feasibility Study for Stage 1 production at its Challenger Gold Project in South Australia. The project leverages the fully permitted Central Gawler Mill and boasts a JORC Mineral Resource Estimate of 313koz Au, including 194koz Au of high-grade fresh ore. The company plans a two-phase approach involving tailings reprocessing followed by high-grade ore introduction. DFS completion and commissioning are targeted by March and the end of 2026, respectively. However, production isn’t expected until late 2026 and financing is still under discussion.

Larimar Therapeutics (LRMR) will host a conference call and webcast on September 29, 2025, at 8:00 am EDT to provide updates on its nomlabofusp clinical development program. The presentation will feature data from the ongoing long-term open-label study evaluating nomlabofusp for the treatment of Friedreich’s ataxia (FA). The company aims to demonstrate the drug’s long-term efficacy and safety in FA patients, addressing a significant unmet medical need. A webcast replay will be available on Larimar’s website.